Drug
Naloxone Ap003
Naloxone Ap003: highest development phase Phase 1, developed by Emergent BioSolutions. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Emergent BioSolutions
Trials
| Drug | Phase | Indication |
|---|---|---|
| 16 mg naloxone AP003 NCT05377255 | Phase 1 | Opioid Overdose |
Latest
No recent events.
Follow Naloxone Ap003 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.